Clinical trials
Prostate Cancer Patients Treated by Radiotherapy clinical trials
Below are recruiting prostate cancer patients treated by radiotherapy clinical trials, each written for real people, not researchers. We’re tracking 257 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+ - NCT06104618RecruitingPhase 2
Enfortumab vedotin for advanced penile cancer
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Phoenix, ArizonaAges 18 years+ - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT07128381RecruitingPhase 1/Phase 2
Axatilimab plus Ruxolitinib for Myelofibrosis and CMML
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
Houston, TexasAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT07633756RecruitingPhase 1
Testing RB1-negative Leiomyosarcoma Treatment with REC-617
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Houston, TexasAges 18 years+ - NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+ - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT07120633Recruiting
CAR-T cell therapy plus BTK inhibitor for high-risk CLL/SLL
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
Xuzhou, JiangsuAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT04128072RecruitingPhase 2
Mogamulizumab plus skin radiation for cutaneous T-cell lymphoma
This trial studies mogamulizumab (an antibody medicine) plus total skin electron beam therapy (whole-skin radiation) to treat cutaneous T-cell lymphoma. It may help by improving skin symptoms and controlling the lymphoma after prior treatments.
CopenhagenAges 18 years+ - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+
Hear when a new Prostate Cancer Patients Treated by Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer patients treated by radiotherapy?
- Yes. Clin2 currently lists 257 recruiting prostate cancer patients treated by radiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer patients treated by radiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer patients treated by radiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Prostate Cancer Patients
- Metastatic Castration-Resistant Prostate Cancer Patients
- Prostate Cancer Patients Undergoing Radical Prostatectomy
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Stage IVB Prostate Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.